OR WAIT 15 SECS
Rita C. Peters is editorial director of BioPharm International, Pharmaceutical Technology, and Pharmaceutical Technology Europe.
A different perspective on controlling fixed costs of biomanufacturing, based on know-how from other industries, provides a competitive edge, says the CEO of Samsung BioLogics.
Digital technologies and information sciences have helped advanced medical science and research, a lesson that was obvious to Dr. Tae Han Kim, CEO and president of Samsung BioLogics, when he was researching new business areas for Samsung about 10 years ago. His recommendation-to enter the biologics drug contract manufacturing market, an area in which it had no prior experience-leveraged the company’s manufacturing and plant construction expertise and has provided the company a competitive edge, he says, in the contract manufacturing market.
Read this article in BioPharm International'sOutsourcing Resources 2018 eBook.
View other articles in BioPharm International's Outsourcing Resources 2018 eBook.
eBook: Outsourcing Resources 2018
When referring to this article, please cite it as R. Peters, “Bigger is Better in Samsung’s Approach to Biomanufacturing," BioPharm International Outsourcing Resources eBook (March 2018).
Related Content:Outsourcing | BioBusiness | Manufacturing | Facility Design and Engineering | Biosimilars and Biobetters | Contract Manufacturing, General | Contract Manufacturing, Drug Substance, API | Contract Manufacturing, Finished Drug Product | Contract Manufacturing, Biopharmaceutical Production